Intestinal absorption and hepatic elimination of drugs in high-fat high-cholesterol diet-induced non-alcoholic steatohepatitis rats: exemplified by simvastatin

被引:5
作者
Li, Ziwei [1 ]
Zhang, Jun [1 ]
Zhang, Yufeng [1 ]
Zhou, Limin [2 ]
Zhao, Jiajia [1 ]
Lyu, Yuanfeng [1 ]
Poon, Long Hin [1 ]
Lin, Zhixiu [3 ]
To, Kenneth Kin Wah [1 ]
Yan, Xiaoyu [1 ]
Zuo, Zhong [1 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Hong Kong, Peoples R China
[2] Hong Kong Baptist Univ, Sch Chinese Med, Kowloon Tong, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Sch Chinese Med, Shatin, Hong Kong, Peoples R China
关键词
hepatic metabolism; high‐ fat high‐ cholesterol diet; intestinal absorption; NASH; P‐ glycoprotein expression; pharmacokinetics; simvastatin; LIVER-DISEASE; P-GLYCOPROTEIN; ENTEROHEPATIC RECIRCULATION; TRANSPORTER EXPRESSION; EFFLUX TRANSPORTERS; CROHNS-DISEASE; CONCISE GUIDE; HYDROXY ACID; IN-VITRO; PHARMACOKINETICS;
D O I
10.1111/bph.15298
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose Altered drug pharmacokinetics is a significant concern in non-alcoholic steatohepatitis (NASH) patients. Although high-fat high-cholesterol (HFHC) diet-induced NASH (HFHC-NASH) rats could simulate the typical dysregulation of cholesterol in NASH patients, experimental investigation on the altered drug pharmacokinetics in this model are limited. Thus, the present study comprehensive investigates the nature of such altered pharmacokinetics using simvastatin as the model drug. Experimental Approach Pharmacokinetic profiles of simvastatin and its active metabolite simvastatin acid together with compartmental pharmacokinetic modelling were used to identify the key factors involved in the altered pharmacokinetics of simvastatin in HFHC-NASH rats. Experimental investigations via in situ single-pass intestinal perfusion and intrahepatic injection of simvastatin were carried out. Histology, Ces1 activities and mRNA/protein levels of Oatp1b2/CYP2c11/P-gp in the small intestine/liver of healthy and HFHC-NASH rats were compared. Key Results Reduced intestinal absorption and more extensive hepatic elimination in HFHC-NASH rats resulted in less systemic exposures of simvastatin/simvastatin acid. In the small intestine of HFHC-NASH rats, thicker intestinal wall with more collagen fibres, increased Ces1 activity and up-regulated P-gp protein decreased the permeability of simvastatin, accelerated the hydrolysis of simvastatin and promoted the efflux of simvastatin acid respectively. In the liver of HFHC-NASH rats, higher hepatic P-gp expression accelerated the hepatic elimination of simvastatin. Conclusion and Implications Altered histology, Ces1 activity and P-gp expression in the small intestine/liver were identified to be the major contributing factors leading to less systemic exposure of drugs in HFHC-NASH rats, which may be applicable to NASH patients.
引用
收藏
页码:582 / 599
页数:18
相关论文
共 64 条
  • [1] Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS297, DOI [10.1111/bph.14752, 10.1111/bph.14749]
  • [2] THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters
    Alexander, Stephen P. H.
    Kelly, Eamonn
    Mathie, Alistair
    Peters, John A.
    Veale, Emma L.
    Armstrong, Jane F.
    Faccenda, Elena
    Harding, Simon D.
    Pawson, Adam J.
    Sharman, Joanna L.
    Southan, Christopher
    Davies, Jamie A.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 : S397 - S493
  • [3] Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology
    Alexander, Steve P. H.
    Roberts, Richard E.
    Broughton, Brad R. S.
    Sobey, Christopher G.
    George, Christopher H.
    Stanford, S. Clare
    Cirino, Giuseppe
    Docherty, James R.
    Giembycz, Mark A.
    Hoyer, Daniel
    Insel, Paul A.
    Izzo, Angelo A.
    Ji, Yong
    MacEwan, David J.
    Mangum, Jonathan
    Wonnacott, Sue
    Ahluwalia, Amrita
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (03) : 407 - 411
  • [4] Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
    Arguello, Graciela
    Balboa, Elisa
    Arrese, Marco
    Zanlungo, Silvana
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2015, 1852 (09): : 1765 - 1778
  • [5] Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
    Benet, LZ
    Izumi, T
    Zhang, YC
    Silverman, JA
    Wacher, VJ
    [J]. JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) : 25 - 31
  • [6] A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content
    Buchman, AL
    Paine, MF
    Wallin, A
    Ludington, SS
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (12) : 2312 - 2315
  • [7] Altered Regulation of Hepatic Efflux Transporters Disrupts Acetaminophen Disposition in Pediatric Nonalcoholic Steatohepatitis
    Canet, Mark J.
    Merrell, Matthew D.
    Hardwick, Rhiannon N.
    Bataille, Amy M.
    Campion, Sarah N.
    Ferreira, Daniel W.
    Xanthakos, Stavra A.
    Manautou, Jose E.
    A-Kader, H. Hesham
    Erickson, Robert P.
    Cherrington, Nathan J.
    [J]. DRUG METABOLISM AND DISPOSITION, 2015, 43 (06) : 829 - 835
  • [8] Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models
    Canet, Mark J.
    Hardwick, Rhiannon N.
    Lake, April D.
    Dzierlenga, Anika L.
    Clarke, John D.
    Cherrington, Nathan J.
    [J]. DRUG METABOLISM AND DISPOSITION, 2014, 42 (04) : 586 - 595
  • [9] Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: a review article
    Chao, Che-Yung
    Battat, Robert
    Al Khoury, Alex
    Restellini, Sophie
    Sebastiani, Giada
    Bessissow, Talat
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (34) : 7727 - 7734
  • [10] Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: Developmental regulation and role in male-specific liver gene expression
    Choi, HK
    Waxman, DJ
    [J]. ENDOCRINOLOGY, 2000, 141 (09) : 3245 - 3255